Our Therapy
Despite significant advances in cancer treatment, including the introduction of immunotherapy, millions of patients worldwide still die of aggressive cancer every year.
For some cancer types, immunotherapy has had limited success. The challenge is that, while cancer cells modify the function of both lymphoid and myeloid immune cells to avoid being killed, conventional immunotherapies activate only T lymphocytes - a subset of lymphoid cells.
Adecto is taking a new approach. We are developing a monoclonal antibody that inhibits the cell surface protein ADAM8 to reprogram both lymphoid and myeloid cells, generating a more potent anti-tumor immune response, including in cancers resistant to conventional immunotherapy.
Our solution does not impact healthy cells and has no adverse effects in vivo.
